April 29 Product: X4 Pharmaceuticals Xolremdi Indication: WHIM Syndrome The FDA approved X4 Pharmaceuticals Xolremdi Monday as the first targeted treatment for WHIM syndrome, an ultra-rare immunodeficiency disease named for its four characteristics: warts, hypogammaglobulinemia, infections and myelokathexis
The solution should be completely clear with no visible particles, cloudiness, or discoloration
Kiprov DD, Herskowitz A, Kim D, et al
Introduction Navigating the journey toward starting or expanding a family is often filled with questions about nutrition, timing, and biological health
How It Works Consultation & Evaluation A licensed medical practitioner assesses your wellness goals and determines if B12 injections may benefit you
Patch clamp electrophysiology studies showed significantly increased synapse density in hippocampal tissue